Chevalier, Grégoire
Laveissière, Arnaud
Desachy, Guillaume
Barnich, Nicolas
Sivignon, Adeline
Maresca, Marc
Nicoletti, Cendrine
Di Pasquale, Eric
Martinez-Medina, Margarita
Simpson, Kenneth William
Yajnik, Vijay
Sokol, Harry
Adegbamigbe, Temitayo
Ahmad, Tariq
Arnott, Ian
Bouhnik, Yoram
Carbonnel, Franck
Colombel, Jean-Frédéric
Doherty, Glen
Cummings, J. R. Fraser
Hébuterne, Xavier
Herfarth, Hans
Kevans, David
de Chambrun, Guillaume Pineton
Nachury, Maria
Nancey, Stéphane
Roblin, Xavier
Tremelling, Mark A. W.
Plassais, Jonathan
Strozzi, Francesco
Cervino, Alessandra
Morra, Rachel
Bonny, Christophe
,
Funding for this research was provided by:
Enterome
Article History
Received: 27 April 2021
Accepted: 1 July 2021
First Online: 23 August 2021
Declarations
:
: The protocols for CrohnOmeter, PREDICT, and MOBIDIC studies were approved by the institutional medical ethics committees:• Program for Protection of Human Subjects from Mount Sinai Hospital, HS#: 17-00029 (GCO#1: 17-0114(0001)).• New England Independent Review Board (NEIRB) (Sponsor Protocol Number: IBD210 / OP097015.ENT).• Office for Research Ethics Committees Northern Ireland (IBD210/OP097015.ENT).• Comité de Protection des Personnes de la Pitié Salpêtrière.Participants were given oral and written information prior to signing the informed consent form.
: Not applicable.
: Jonathan Plassais, Alessandra Cervino, and Christophe Bonny are among the inventors of a patent protecting tools for assessing FimH blockers’ therapeutic efficiency (WO2019076931). All other authors declare that they have no competing interests.